A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
Recruiting · Phase 1 · NCT06807632
Conditions: Extensive-stage Small-cell Lung Cancer
At a glance
- Research payments reported, 2025
- $34,771
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 24
About the trial
- Sponsor
- Memorial Sloan Kettering Cancer Center (with Daiichi Sankyo)
- Tested
- Valemetostat (drug), Atezolizumab (drug)
- Dates
- Started 2025-01-29; completion 2027-01
- Results posted
- Not yet
This study will test whether valemetostat in combination with atezolizumab is a safe treatment that causes few or mild side effects in people with extensive-stage small cell lung cancer (SCLC). The researchers will test different doses of valemetostat to find the highest dose that causes few or mild side effects in participants. After the dose is found, researchers will test it in a new group of participants to learn more about the safety of the study treatment and see if it is an effective treatment for extensive-stage SCLC.
From ClinicalTrials.gov, last updated 2026-11-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $34,771 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Memorial Hospital for Cancer and All $34,771
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.